Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001127602-20-018084
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-28 18:07:28
Reporting Period:
2020-05-27
Accepted Time:
2020-05-28 18:07:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643746 H. Lorence Kim C/o Moderna, Inc.
200 Technology Square
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-27 222,365 $14.22 1,424,875 No 4 M Direct
Common Stock Acquisiton 2020-05-27 18,635 $12.21 1,443,510 No 4 M Direct
Common Stock Disposition 2020-05-27 241,000 $51.13 1,202,510 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-05-27 18,635 $0.00 18,635 $12.21
Common Stock Stock Option (Right to Buy) Disposition 2020-05-27 222,365 $0.00 222,365 $14.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
55,909 2027-02-23 No 4 M Direct
666,044 2028-02-28 No 4 M Direct
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
  2. 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.
  3. 458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years).